Gennex Laboratories share price
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Gennex Laboratories Ltd · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1996
Last close ₹8.88up ₹0.29 (3.38%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹8.59.
27 Oct: open ₹8.65, high ₹9.15, low ₹8.50
52-week range of traded prices to 27 Oct 2026
₹7.05Low, 30 Mar 2026₹17.25High, 28 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹216 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.74
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.97
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,39,015
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore.Gennex Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +24.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +7.3%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹35 Crdown 5.55%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹3.96 Crup 32.09%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 11.4%
Revenue by quarter
Peak revenue ₹37 Cr, quarter to Mar 2026; lowest ₹23 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.7 | 25.3 | 23.3 | 25.6 | 29.3 | 28.2 | 36.7 | 34.7 |
| Net profit | 4.2 | 4.2 | 1.5 | 4.1 | 4.5 | 4.5 | 3.0 | 4.0 |
| Net margin | 16.8% | 16.7% | 6.5% | 16.2% | 15.5% | 15.8% | 8.2% | 11.4% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹120 Crup 26.73%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹16 Crup 14.90%
- Net margin
- 13.5%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹44 Cr, differs from its quarters added, ₹47 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 44 | 56 | 56 | 60 | 61 | 65 | 67 | 95 | 120 |
| Net profit | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 12 | 14 | 16 |
| Net margin | 6.5% | 1.9% | 4.0% | 3.3% | 6.8% | 6.4% | 7.0% | 17.7% | 14.8% | 13.5% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, "Bulk Drugs, Biotech Products and lntermediates", which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Gennex Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 2% of 925 trading days over the last 5 years.
LowestHighest
Its median21.99Industry median28.51
Price to book
At or below today's level on 1% of 993 trading days over the last 5 years.
LowestHighest
Its median1.93Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −40.8% | +8.1% | −45.2% | 0.0% |
| 3 years | +8.3% | +37.1% | −21.0% | 0.0% |
| 5 years | +12.8% | +16.0% | −2.8% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 4,816 | 0.01% | ₹48,000 |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 2,271 | 0.01% | ₹23,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Gennex Laboratories competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Gennex Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Ambalal Sarabhai EnterprisesAMBALALSA | 268 | 19.74 | 1.69 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 Everest OrganicsEVERESTO | 255 | 48.50 | 3.38 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 BDH IndustriesBDH | 242 | 20.65 | 3.14 | +44.8% | +22.9% | 16.1% | 18.2% | 1.19% |
 Zenotech LaboratoriesZENOTECH | 235 | – | 2.47 | +4.6% | – | −2.6% | −3.9% | 0.00% |
 Sat Kartar LifeSATKARTAR | 212 | 11.11 | 2.43 | – | – | 26.3% | – | 0.52% |
 Accretion PharmaceuticalsACCPL | 206 | 21.27 | 3.76 | +56.2% | +42.3% | 27.6% | – | 0.00% |
 Sanjivani ParanteralSANJIVIN | 205 | – | 4.24 | +13.2% | – | – | 20.2% | 0.00% |
 Nectar LifesciencesNECLIFE | 205 | – | 0.35 | −99.7% | – | −31.9% | −15.4% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Gennex Laboratories announcements
Oct 2026
Sep 2026
8 Sep · Approval Of Additional Products From Drugs Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited
Gennex Laboratories share price by year
Each calendar year to 2025.Gennex Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 14.30 | −12.4% | 18.71 | 11.18 |
| 2024 | 16.33 | −2.9% | 27.87 | 13.58 |
| 2023 | 16.81 | +163.1% | 17.25 | 4.99 |
| 2022 | 6.39 | −42.2% | 12.48 | 6.01 |
| 2021 | 11.05 | +135.6% | 12.19 | 3.80 |
| 2020 | 4.69 | +79.7% | 5.78 | 1.41 |
| 2019 | 2.61 | −31.5% | 4.51 | 2.39 |
| 2018 | 3.81 | −33.5% | 6.25 | 3.05 |
| 2017 | 5.73 | −7.1% | 7.57 | 3.33 |
| 2016 | 6.17 | −36.5% | 13.77 | 6.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 26 Oct 2026 | 8.74 | 8.87 | 8.53 | 8.59 | 8.64 | 2,21,331 |
| 23 Oct 2026 | 8.95 | 8.99 | 8.50 | 8.70 | 8.64 | 2,30,459 |
| 22 Oct 2026 | 8.99 | 8.99 | 8.76 | 8.85 | 8.89 | 1,40,496 |
| 21 Oct 2026 | 9.10 | 9.20 | 8.60 | 8.90 | 8.85 | 3,62,954 |
| 19 Oct 2026 | 9.20 | 9.20 | 8.80 | 8.97 | 8.90 | 3,35,227 |
| 16 Oct 2026 | 9.30 | 9.47 | 8.90 | 9.02 | 9.03 | 8,42,214 |
| 15 Oct 2026 | 9.21 | 9.43 | 9.21 | 9.28 | 9.33 | 2,37,232 |
| 14 Oct 2026 | 9.25 | 9.55 | 9.25 | 9.43 | 9.44 | 2,50,105 |
| 13 Oct 2026 | 9.59 | 9.83 | 8.27 | 9.21 | 8.99 | 8,29,282 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 21 Jul 2022 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 14 Dec 2009 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- BSE code
- 531739
- ISIN
- INE509C01026
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.gennexlab.com
- CIN
- L24230TG1990PLC011168
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1990
- Registered office
- SY No 133, IDA Bollaram, Jinnaram Mandal, Medak 502325, Telangana
- Share registrar
- R&D Infotech Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments